Cover - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2025 |
Mar. 13, 2026 |
Jun. 30, 2025 |
|
| Cover [Abstract] | |||
| Document Type | 10-K | ||
| Amendment Flag | false | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Document Period End Date | Dec. 31, 2025 | ||
| Document Fiscal Period Focus | FY | ||
| Document Fiscal Year Focus | 2025 | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity File Number | 001-39318 | ||
| Entity Registrant Name | Lantern Pharma Inc. | ||
| Entity Central Index Key | 0001763950 | ||
| Entity Tax Identification Number | 46-3973463 | ||
| Entity Incorporation, State or Country Code | DE | ||
| Entity Address, Address Line One | 1920 McKinney Avenue | ||
| Entity Address, Address Line Two | 7th Floor | ||
| Entity Address, City or Town | Dallas | ||
| Entity Address, State or Province | TX | ||
| Entity Address, Postal Zip Code | 75201 | ||
| City Area Code | (972) | ||
| Local Phone Number | 277-1136 | ||
| Title of 12(b) Security | Common Stock, $0.0001 par value | ||
| Trading Symbol | LTRN | ||
| Security Exchange Name | NASDAQ | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Interactive Data Current | Yes | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | false | ||
| Entity Shell Company | false | ||
| Entity Public Float | $ 33,935,133 | ||
| Entity Common Stock, Shares Outstanding | 11,254,697 | ||
| Documents Incorporated by Reference [Text Block] | Portions of the registrant’s definitive proxy statement for the registrant’s 2026 Annual Meeting of Stockholders to be filed pursuant to Regulation 14A within 120 days of the registrant’s year ended December 31, 2025 are incorporated herein by reference into Part III of this Annual Report on Form 10-K. | ||
| ICFR Auditor Attestation Flag | false | ||
| Document Financial Statement Error Correction [Flag] | false | ||
| Entity Listing, Par Value Per Share | $ 0.0001 | ||
| Auditor Firm ID | 274 | ||
| Auditor Opinion [Text Block] | We have audited the accompanying consolidated balance sheets of Lantern Pharma Inc. and Subsidiaries (the “Company”) as of December 31, 2025 and 2024, and the related consolidated statements of operations, comprehensive loss, stockholders’ equity, and cash flows for each of the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2025 and 2024, and the consolidated results of their operations and their cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America. | ||
| Auditor Name | EisnerAmper LLP | ||
| Auditor Location | Philadelphia, Pennsylvania |